AI
CYTK icon

Atom Investors’s Cytokinetics CYTK Stock Holding History

Atom Investors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,350
Closed -$1.34M – 870
2026
Q1 		$1.34M Buy
+20,350
New +$1.29M 0.1% 310
2024
Q3 		– Sell
-3,986
Closed -$216K – 496
2024
Q2 		$216K Buy
+3,986
New +$241K 0.02% 418
2020
Q4 		– Sell
-103,957
Closed -$2.25M – 420
2020
Q3 		$2.25M Sell
103,957
-152,880
-60% -$3.58M 0.21% 114
2020
Q2 		$6.05M Sell
256,837
-4,886
-2% -$91.6K 0.39% 45
2020
Q1 		$3.09M Buy
261,723
+224,322
+600% +$2.86M 0.27% 90
2019
Q4 		$397K Buy
+37,401
New +$384K 0.03% 184

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atom Investors's CYTK Position: Q2 2026 in Review

Atom Investors sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 20,350 shares — an estimated $1.34M sold.

Atom Investors first reported a position in CYTK in Q4 2019 and held it in 6 quarters. The position peaked at $6.05M in Q2 2020. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Atom Investors reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Atom Investors sold 20,350 Cytokinetics shares in Q2 2026, an estimated $1.34M.
  • Atom Investors first reported a position in Cytokinetics in Q4 2019 and held it in 6 quarters.
  • Atom Investors's Cytokinetics position peaked at $6.05M in Q2 2020.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.